CMO of OncoMed Pharma resigns
OncoMed Pharmaceuticals, a clinical-stage pharmaceutical company, announced that Jakob Dupont has resigned from his positions as the company’s senior vice president and chief medical officer. Mr. Dupont’s decision was based upon personal and family-related issues. He leaves the position after five years working with the company. He will leave his role at the beginning of next year and is expected to return to Genentech/Roche to take up a position within oncology clinical development.
“While this was a very difficult decision for me to make, pursuing this new opportunity is the right thing for me and my family,” said Mr. Dupont. “I am truly proud of our achievements at OncoMed, including delivering seven investigational new drugs into multiple clinical trials, with two new INDs expected in the near future. I know that I leave OncoMed well-positioned for continued success and I am excited about the future of the company.”
“It is with great sadness that we announce Jakob’s resignation. During his five-year tenure, Jakob has built an impressive clinical development team that is advancing seven novel anti-cancer investigational drugs in the clinic, including earlier this year, completion of enrollment in our YOSEMITE and PINNACLE randomized Phase 2 trials. Given the extensive strength and depth of OncoMed’s product development organization, I am confident that we will be able to deliver our development objectives on time and on budget, including Phase 2 results for lead investigational drugs demcizumab and tarextumab, filing two new immuno-oncology INDs between now and mid-2017, and multiple opt-in data packages to our partners in 2017,” said Paul Hastings, CEO and chairman of OncoMed. “Although we regret Jakob’s departure, we respect his decision and wish him all the best in his new position, and thank him for his many significant contributions to the company.”
OncoMed has begun the process to identify candidates to replace Mr. Dupont as CMO.